Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 24, 2007

View Archived Issues

Positive preclinical results of SB-939 in hematological cancer models

New agents for treating diabetes disclosed in recent patent literature

New oncolytic agents disclosed in recent patent literature

Ongoing phase I/II study reveals activity of ABT-263 in lymphoid malignancies

Novel 5-HT2C receptor agonists emerge from Takeda R&D

Encouraging results seen with bevacizumab in glioblastoma multiforme

Raloxifene may benefit postmenopausal women with schizophrenia

Tamoxifen evaluated as anti-mania treatment in women with bipolar affective disorder

Immusol changes name to ItherX

Ablynx extends drug discovery and development alliance for Nanobodies with Novartis

Ablynx reports positive results from phase I study of its Nanobody antithrombotic therapeutic

Pfizer enters agreement to acquire CovX

Raptor acquires exclusive worldwide license to EC Cysteamine for nephropathic cystinosis

Alseres initiates POET-2 phase III clinical trial program for altropane

CuraGen and TopoTarget initiate phase II clinical trial of belinostat

Dosing begins in phase I clinical study of dopaminergic stabilizer ACR-343 for PD

Sunesis and the MMRC enter into collaboration to study SNS-032 in multiple myeloma

Meldex files regulatory dossier in Europe for approval of Uluru's OraDisc B

Phase II study generates positive results for DDP-225 in IBS-d

Eladur shows improved pain control in phase IIa study in postherpetic neuralgia

New therapeutic approach for inherited form of hypoparathyroidism

Exelixis submits data report for IND candidate XL-139 to Bristol-Myers Squibb

VGF neuropeptide gene involved in antidepressant effects of exercise

FDA issues nonapprovable letter for Pharmacyclics' NDA for Xcytrin for NSCLC brain metastases

FDA accepts Otsuka Pharmaceutical's NDA for tolvaptan for heart failure and hyponatremia

Lexicon summits IND application to the FDA for LX-1032 for carcinoid syndrome

Galenica's acquisition of Aspreva Pharmaceuticals is granted Canadian approval

FDA issues approvable letter for Jazz Pharmaceuticals' Luvox for SAD and OCD

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...